Veos Pharmaceuticals Launches ThymoTropin™ to Support Muscle Health and Preservation on Weight Loss and Aging Journeys

Clinically Proven Myostatin-Targeting Formula to Enhance Muscle Growth, Repair, and Endurance

MADRID, SPAIN / ACCESS Newswire / January 16, 2025 / Veos Pharmaceuticals, a leading innovator with a portfolio of nearly 40 products spanning the EU, US, and Canada, today announced the launch of ThymoTropin™, a revolutionary over-the-counter (OTC) solution for muscle growth, repair, and preservation. ThymoTropin™, powered by clinically validated thymol and carvacrol, represents a first-of-its-kind product targeting myostatin regulation, a critical mechanism for maintaining muscle mass and performance.

As part of Veos Pharma’s commitment to delivering science-backed innovations, ThymoTropin™ addresses the unique needs of individuals experiencing muscle loss due to aging, chronic disease, or weight management regimens, including GLP-1 treatments and calorie-restricted diets.

Filling a Critical Gap in Muscle Health

More than 50% of individuals undergoing weight loss or battling chronic illnesses face muscle loss, impacting their mobility, strength, and overall health. ThymoTropin™ is formulated to counteract this decline by preserving and enhancing muscle mass through its innovative dual-action mechanism:

• Read moreFossil launches its first smartwatch on the Qualcomm Snapdragon Wear 3100 platform

  Clinically proven myostatin regulation for targeted muscle preservation.

• Support for lean muscle growth and endurance, validated through preclinical and clinical studies.

“At Veos Pharmaceuticals, we are committed to addressing critical health gaps with effective, science-driven solutions,” said Dr. Bassam Damaj, Executive Chairman of Veos Pharma. “ThymoTropin™ is a game-changer in muscle health, offering proven benefits for individuals managing muscle loss while aligning with modern health goals, including weight loss and aging-related care.”

Clinically Backed, Patented Innovation

ThymoTropin™ is supported by a robust patent portfolio, including:

• Read moreConwy Care Home Multi-Professional Response wins Secure I.T. Environments Sponsored award at Betsi Cadwaladr University Health Board Achievement Awards

  US Patent No. 11,135,178: Enhancing Muscle Growth via Monoterpenes

• CA Patent No. 2,964,239: Applications of Monoterpenes in Muscle Health

• EP Patent No. 3191086: Monoterpene Formulations for Muscle Enhancement

• PT Patent No. 3191086: Monoterpenes for Myostatin Regulation

Clinical results demonstrate up to a 50% increase in muscle mass and 37% improvement in endurance. ThymoTropin™’s unique focus on myostatin regulation differentiates it from traditional protein supplements, making it a superior solution for muscle health.

Targeted Nutrition for Growing Market Needs

The global market for muscle health and repair products continues to grow, driven by increasing demand from aging populations, oncology patients, and fitness-conscious individuals. ThymoTropin™ directly addresses these needs by providing:

• Muscle preservation during weight loss

• Enhanced recovery and repair

• Support for aging-related muscle decline

In a competitive landscape dominated by protein supplements like Abbott’s Protality™ and Nestle Boost, ThymoTropin™ stands out with its clinically validated myostatin regulation mechanism. Unlike traditional products, ThymoTropin™ offers targeted efficacy without unnecessary calories or sugars, making it an ideal solution for modern health-conscious consumers.

Growing Market Opportunity and Competitive Landscape

The global muscle health and nutritional support market is projected to exceed $15 billion by 2025, driven by increasing demand from aging populations, oncology supportive care, and weight management solutions. Competitor products such as Abbott’s Protality™ and Nestle Boost™ have collectively generated impressive sales, with:

• Protality™ generates an estimated annual revenue of $300 million and a 15% market share.

• Nestle Boost® generates an estimated $500 million annually with a 25% market share.

• Traditional whey protein supplements lead with over $8 billion in annual revenue and a dominant 60% market share.

While competitor products focus on general protein supplementation, ThymoTropin™ sets itself apart by targeting myostatin regulation, offering a precise and effective solution for muscle growth and preservation without unnecessary calories or sugars.

Available as an Ingredient for B2B Applications

ThymoTropin™ is offered as a premium ingredient for business-to-business (B2B) formulations. This enables manufacturers in the health, nutrition, and functional food sectors to incorporate ThymoTropin™’s proven myostatin-targeting benefits into their products, meeting growing consumer demand for advanced muscle health solutions. Veos Pharma partners with businesses to provide customized solutions and ensure seamless integration into existing product lines.

About Veos Pharmaceuticals

Headquartered in Madrid, Spain, Veos Pharmaceuticals is a global leader in health innovation with a portfolio of nearly 40 products across the EU, US, and Canada. The company specializes in OTC solutions, biostimulants, and advanced nutritional products aimed at improving quality of life. Veos Pharma’s flagship products include Ocufresh®,BioPropello™, OleoSorb™, VEOX-Preserv™, and ThymoTropin™.

For more information, contact:

Dr. Bassam Damaj
Executive Chairman
Veos Pharmaceuticals, SL
Email: info@veospharma.com
Website: www.veospharma.com

Protality™ is a trademark of Abbott Laboratories. Boost® is a trademark of Nestlé

References:

https://www.grandviewresearch.com/industry-analysis/sports-supplement-market

Nestlé, S.A. (SWX: NESN) disclosures and Abbott Laboratories (NYSE: ABT) disclosures

Forward-Looking Statements: This press release may contain forward-looking statements that involve risks and uncertainties. Veos Pharmaceuticals assumes no obligation to update or revise these statements after the date of publication.

SOURCE: Veos Pharmaceuticals, SL

View the original press release on ACCESS Newswire